---
figid: PMC12205216__MCO2-6-e70278-g003
figtitle: Natural products targeting TGF‐B pathway in treatment of liver cancer
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12205216
filename: MCO2-6-e70278-g003.jpg
figlink: /pmc/articles/PMC12205216/figure/F8/
number: F8
caption: Natural products targeting TGF‐β pathway in treatment of liver cancer. The
  schematic illustrates the TGF‐β signaling pathway implicated in liver cancer, emphasizing
  the inhibitory effects of various natural products. The natural compounds that inhibit
  TGF‐β signaling in different liver cancer cell lines (HCC‐LM3, HepG2, SK‐HEP‐1,
  SMMC‐7721, Bel‐7402, Huh7, H22) are depicted. The canonical and noncanonical pathways
  are shown, detailing the downstream signaling events and their impact on epithelial–mesenchymal
  transition (EMT) suppressor genes, extracellular matrix degrader genes, cell proliferative
  genes, and apoptotic‐trigger genes. Natural products such as fisetin (FiT), tanshinone
  IIA (TsH), oroxylin A (OrA), sulforaphane (SuF), Stellera chamaejasme L (ScL), Jiedu
  recipe (JeR), Chinese dragon's blood extract (CdB), salvanolic acid B (Salv B),
  ailanthoidol (AllD), echinacoside (Ech), and solanine (SolA) inhibit various targets
  within these pathways. AllD, ailanthoidol; Akt, akinase; Bel‐7402, human liver cancer
  cell line; Bel‐7404, human liver cancer cell line; Bcl‐2, B‐cell lymphoma 2; CdB,
  Chinese Dragon's blood extract; E‐cadherin, epithelial cadherin; Ech, echinacoside;
  EMT, epithelial–mesenchymal transition; ERK1/2, extracellular signal‐regulated kinase
  1/2; FiT, fisetin; H22, human liver cancer cell line; HCC‐LM3, human liver cancer
  cell line; HepG2, human liver cancer cell line; JNK, c‐Jun N‐terminal kinase; JeR,
  Jiedu recipe; MAPK, mitogen‐activated protein kinase; MMP‐2, matrix metalloproteinase‐2;
  MMP‐9, matrix metalloproteinase‐9; N‐cadherin, neural cadherin; p38, mitogen‐activated
  protein kinase p38; P‐Smad3, phosphorylated Smad3; ScL, Stellera chamaejasme L;
  SK‐HEP‐1, human liver cancer cell line; Smad2, mothers against decapentaplegic homolog
  2; Smad3, mothers against decapentaplegic homolog 3; Smad4, mothers against decapentaplegic
  homolog 4; Smad3 EPSM, mutant Smad3 with phosphorylation site mutation in the linker
  region; Smad3 3S‐A, mutant Smad3 with phosphorylation site mutation in the C terminus;
  SMMC‐7721, human liver cancer cell line; SolA, solanine; SuF, sulforaphane; TGF‐β,
  transforming growth factor beta; TsH, tanshinone IIA
papertitle: 'Transforming Growth Factor‐β Pathway: Biological Functions and Therapeutic
  Targets'
reftext: Reham Hassan Mekky, et al. MedComm (2020). 2025 Jul;6(7).
year: '2025'
doi: 10.1002/mco2.70278
journal_title: MedComm
journal_nlm_ta: MedComm (2020)
publisher_name: Wiley
keywords: angiogenesis | apoptosis | cancer progression | natural compounds | TGF‐β
  pathway | therapeutic modulation
automl_pathway: 0.9223227
figid_alias: PMC12205216__F8
figtype: Figure
redirect_from: /figures/PMC12205216__F8
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12205216__MCO2-6-e70278-g003.html
  '@type': Dataset
  description: Natural products targeting TGF‐β pathway in treatment of liver cancer.
    The schematic illustrates the TGF‐β signaling pathway implicated in liver cancer,
    emphasizing the inhibitory effects of various natural products. The natural compounds
    that inhibit TGF‐β signaling in different liver cancer cell lines (HCC‐LM3, HepG2,
    SK‐HEP‐1, SMMC‐7721, Bel‐7402, Huh7, H22) are depicted. The canonical and noncanonical
    pathways are shown, detailing the downstream signaling events and their impact
    on epithelial–mesenchymal transition (EMT) suppressor genes, extracellular matrix
    degrader genes, cell proliferative genes, and apoptotic‐trigger genes. Natural
    products such as fisetin (FiT), tanshinone IIA (TsH), oroxylin A (OrA), sulforaphane
    (SuF), Stellera chamaejasme L (ScL), Jiedu recipe (JeR), Chinese dragon's blood
    extract (CdB), salvanolic acid B (Salv B), ailanthoidol (AllD), echinacoside (Ech),
    and solanine (SolA) inhibit various targets within these pathways. AllD, ailanthoidol;
    Akt, akinase; Bel‐7402, human liver cancer cell line; Bel‐7404, human liver cancer
    cell line; Bcl‐2, B‐cell lymphoma 2; CdB, Chinese Dragon's blood extract; E‐cadherin,
    epithelial cadherin; Ech, echinacoside; EMT, epithelial–mesenchymal transition;
    ERK1/2, extracellular signal‐regulated kinase 1/2; FiT, fisetin; H22, human liver
    cancer cell line; HCC‐LM3, human liver cancer cell line; HepG2, human liver cancer
    cell line; JNK, c‐Jun N‐terminal kinase; JeR, Jiedu recipe; MAPK, mitogen‐activated
    protein kinase; MMP‐2, matrix metalloproteinase‐2; MMP‐9, matrix metalloproteinase‐9;
    N‐cadherin, neural cadherin; p38, mitogen‐activated protein kinase p38; P‐Smad3,
    phosphorylated Smad3; ScL, Stellera chamaejasme L; SK‐HEP‐1, human liver cancer
    cell line; Smad2, mothers against decapentaplegic homolog 2; Smad3, mothers against
    decapentaplegic homolog 3; Smad4, mothers against decapentaplegic homolog 4; Smad3
    EPSM, mutant Smad3 with phosphorylation site mutation in the linker region; Smad3
    3S‐A, mutant Smad3 with phosphorylation site mutation in the C terminus; SMMC‐7721,
    human liver cancer cell line; SolA, solanine; SuF, sulforaphane; TGF‐β, transforming
    growth factor beta; TsH, tanshinone IIA
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFB1
  - TGFB2
  - TGFB3
  - BCR
  - IGKV3D-20
  - BAAT
  - THOP1
  - LINC00273
  - TOP1
  - TOP1MT
  - TOP3A
  - TOP3B
  - TOP2A
  - TOP2B
  - RGMB
  - Cancer
  - Liver Cancer
---
